Eudesmic acid-polyoxomolybdate organo-conjugate as novel anticancer agent

Abstract

In this work, trimethylated gallic acid (Eudesmic acid, EU) was selected for the synthesis of an organo-conjugate (EU2POMo) from TRIS modified Anderson-type manganese polyoxomolybdate (POMo) for the first time. EU2POMo was synthesized through amide bonding between POMo and EU using carbodiimide coupling strategy. Some of the quantum chemical properties of POMo and EU2POMo beside the DFT and TD-DFT calculations were done using the Gaussian program. The cytotoxicity was studied on breast cancer cell lines (MCF-7 and MDA-MB-231) comparing the Human Umbilical Vein Endothelial Cell line (HUVEC) using the MTT method. The cellular uptake was determined using the ICP-MS method, and the apoptosis value was checked by the flow cytometry technique on the MDA-MB-231 cell line. The structure was approved by FTIR, NMR spectroscopy as well as elemental analysis. Quantum chemical calculations proposed better stability and lower chemical potential for EU2POMo, and internal energy and dipole moment were higher in the EU2POMo. Both POMo and EU2POMo showed reasonable anti-cancer effects on breast cancer cell lines (MCF-7 and MDA-MB-231), and the results were somewhat in favor of POMo. Interestingly, EU2POMo showed no significant cytotoxicity on the HUVEC and was safer than POMo. Cellular uptake (33.5 versus 29.2) and apoptosis value (28 versus 15) in the case of EU2POMo were slightly better than POMo. In conclusion, this study aimed to introduce a novel, potent and safe anti-cancer Anderson type polyoxometalate to cancer studies. Based on results, this conjugate has sufficient potential for further cancer chemotherapy assessments, specifically breast cancer. (C) 2021 Elsevier B.V. All rights reserved.